Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis

Brodalumab is a fully human monoclonal antibody targeting the IL‐17 receptor A leading to an inhibition of the biological effect of IL‐17A, IL‐17F, IL‐17A/F heterodimer, IL‐17C and IL‐17E isoforms. It has shown to be efficacious in the treatment of moderate to severe plaque psoriasis (210 mg adminis...

Descripción completa

Detalles Bibliográficos
Autores principales: Timmermann, Stine, Hall, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850607/
https://www.ncbi.nlm.nih.gov/pubmed/30661290
http://dx.doi.org/10.1111/bcpt.13202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850607/
https://www.ncbi.nlm.nih.gov/pubmed/30661290
http://dx.doi.org/10.1111/bcpt.13202

Ejemplares similares